Close
Food, measuring tape and weights
12 January 2023
Why is understanding hypermetabolism important in ALS…
Doctor writing notes
6 January 2023
Can signs of MND be detected before…
Keyboard, stethoscope and clipboard
21 December 2022
Improving clinical endpoints to help improve MND…
Four photos of MND researchers
15 December 2022
Conversations with…4 international MND researchers
An image of a Stethoscope, a pill bottle, some pills and a syringe
7 December 2022
4 MND clinical trial updates to end…
Immune cells
6 December 2022
Breaking down the MIROCALS clinical trial results
2 December 2022
Cells behaving badly: what’s going wrong in…
Members of the Research Development team
30 November 2022
Symposium Blogathon: Behind the scenes with the…
Driving research forward – £1 million awarded to research into cutting-edge therapies for MND

Driving research forward – £1 million awarded to research into cutting-edge therapies for MND

Reading Time: 4 minutes In 2021, the MND Association, the My Name’5 Doddie Foundation and medical research charity LifeArc established a joint fund – the Motor Neuron Disease Translational Fund – to support translational research in motor neurone disease. In January 2023, £1 million was awarded to researchers at University College London (UCL) to progress two promising new therapies,…

Why is understanding hypermetabolism important in ALS outcomes?

Why is understanding hypermetabolism important in ALS outcomes?

Reading Time: 7 minutes Shyuan’s talk was titled ‘Investigating the role of hypermetabolism in ALS’ (C06 in the abstract book) and discussed the research being carried out by her team to try and understand the mechanisms driving hypermetabolism in ALS and what hypermetabolism means clinically for people living with the disease. This blog details Shyuan’s work and looks closely at her observations on hypermetabolism in relation to ALS.

Can signs of MND be detected before symptoms appear?

Can signs of MND be detected before symptoms appear?

Reading Time: 6 minutes It has been suggested that there might be a pre-symptomatic stage of MND, where the disease is active and occurring within a person but no symptoms are showing. There is currently little research in this area and a lack of evidence of a pre-symptomatic stage of the disease. However, if it can be shown that there is a pre-symptomatic stage which can be measured, this could be very useful in helping people with MND to get treatment as early as possible. Dr Michael Benatar, from the University of Miami, has been looking into this by studying the development of MND and how the disease presents in people who have a high risk of developing it.

Improving clinical endpoints to help improve MND clinical trial outcomes

Improving clinical endpoints to help improve MND clinical trial outcomes

Reading Time: 5 minutes What is a clinical endpoint?

A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.

To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.

Conversations with…4 international MND researchers

Conversations with…4 international MND researchers

Reading Time: 3 minutes Last week at the 33rd International Symposium on ALS/MND, we heard some exciting updates on a wide range of research happening all over the world. The pace of ALS/MND research has drastically increased over recent years and we now have a better understanding about the underlying biology of the disease which is crucial to being able to identify new potential drug targets.

4 MND clinical trial updates to end 2022

4 MND clinical trial updates to end 2022

Reading Time: 6 minutes Over the last year ALS/MND clinical trials have taken centre stage, with more trials than ever opening for recruitment in the UK, the news of promising results from some trials and the approval of drugs by some regulatory authorities. With the year coming to an end, we thought we would roundup some recent clinical trial updates that were presented at the 33rd International Symposium on ALS/MND.

Cells behaving badly: what’s going wrong in immune cells in MND?

Cells behaving badly: what’s going wrong in immune cells in MND?

Reading Time: 5 minutes A recent paper published in the Journal Neurology: Neuroimmunology & Neuroinflammation has revealed new insights into how immune cells behave in MND. This work, which is the result of a collaboration between researchers across different universities, aimed to uncover more about the role of the immune system in MND progression. The study used blood samples…